NovoSeven

Type: Product
Name: NovoSeven
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Update: China Biologic Acquires Additional Interest In Guizhou Facility - Shares Rise

By Trevor Lowenthal :Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ: CBPO ), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued ... [Published BioPortfolio - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Update: China Biologic Acquires Additional Interest In Guizhou Facility - Shares Rise

Summary China Biologic acquires additional equity in the Guizhou Taibang Facility. Since this will likely lead to earnings accretion, I reiterate my bull thesis on China Biologic. This event came as a surprise, since I anticipated that funds from the ... [Published Seeking Alpha - Aug 26 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

NOVOSEVEN RT (Coagulation Factor Viia (Recombinant)) Kit [Novo Nordisk]

First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Novo Nordisk's Earnings Rise on Solid Victoza, Levemir Sales

Novo Nordisk ( NVO ) reported second-quarter 2014 earnings of 48 cents per American Depository Receipt (:ADR), higher than the year-ago earnings of 44 cents.In the reported quarter, revenues increased 6% to $3.9 billion year over year. The top-line was ... [Published Yahoo! Finance - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 1 reports

Novo Nordisk beats estimates as net profit grows 4%

Danish diabetes care giant Novo Nordisk (NOV: N) released first-half 2014 financial results this morning, showing that sales increased 7% in local currencies and 1% in Danish kroner to 41.97 billion kroner ($7.57 billion).Operating profit rose 12% in ... [Published Pharma Letter - Aug 07 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Update: China Biologic Products - Strong Q2 Earnings Growth

By Trevor Lowenthal :Before earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ: CBPO ), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued ... [Published BioPortfolio - Aug 06 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

The New Anticoagulants: Indications and Risks

Editor's Note: Since October 2010, the US Food and Drug Administration (FDA) has approved 3 new anticoagulants that, for the first time, offer patients with such conditions as stroke in the setting of atrial fibrillation (AF), deep vein thrombosis, and ... [Published Diabetes Care - Jul 24 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 1 reports

FDA Approves NovoSeven® RT for the Treatment of Glanzmann's Thrombasthenia (GT) With Refractoriness

PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative ... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Update: China Biologic Acquires Additional Interest In Guizhou Facility - Shares Rise"
Chief executive Lars Rebien Sorensen commented: "We are satisfied with the financial results achieved in a challenging first half of 2014. Tresiba [insulin degludec] is doing well in key markets and the DEVOTE trial continues to progress ahead of plans. This has enabled us to shorten further the timeline towards the interim analysis and a potential US launch of Tresiba. Furthermore, with the  positive opinion for Xultophy [insulin degludec/liraglutide] from the EU regulatory authorities, we have passed a key milestone in bringing the first insulin and GLP-1 combination product to the market."
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mf7sbv/novoseven_rt) has announced the addition of the "Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering...

More Content

All (13) | News (8) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Update: China Biologic Acquires Additional Inte... [Published BioPortfolio - Aug 26 2014]
Update: China Biologic Acquires Additional Inte... [Published Seeking Alpha - Aug 26 2014]
NOVOSEVEN RT (Coagulation Factor Viia (Recombin... [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Novo Nordisk's Earnings Rise on Solid Victoza, ... [Published Yahoo! Finance - Aug 08 2014]
Novo Nordisk beats estimates as net profit grow... [Published Pharma Letter - Aug 07 2014]
Update: China Biologic Products - Strong Q2 Ear... [Published BioPortfolio - Aug 06 2014]
Update: China Biologic Products - Strong Q2 Ear... [Published Seeking Alpha - Aug 06 2014]
China Biologic Products Earnings Preview [Published Seeking Alpha - Aug 05 2014]
The New Anticoagulants: Indications and Risks [Published Diabetes Care - Jul 24 2014]
FDA Approves NovoSeven® RT for the Treatment of... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
Fact Sheet for Novo-Nordisk A/S [Published Able2Act - Jul 24 2008]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
NOVOSEVEN RT (Coagulation Factor Viia (Recombin... [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Updated Date: Aug 19, 2014 EST ...
FDA Approves NovoSeven® RT for the Treatment of... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]
PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mf7sbv/novoseven_rt) has announced the addition of the "Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering. The competitive ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.